I-Mab shares rise 5.65% premarket after Everest Medicines' positive H1 2025 earnings report.

I-Mab rose 5.65% in premarket trading, with Everest Medicines, a biopharmaceutical company, announcing its interim results for the first half of 2025. The company reported accelerating its transformation into a leading global biopharmaceutical company by deepening its 'dual-engine' strategy, which includes building a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T.